Cargando…

Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial

PURPOSE: Colorectal cancer is becoming an increasing concern in the middle-aged population of Iran. This study aimed to compare the preliminary results of short-course and long-course neoadjuvant chemoradiotherapy treatment for rectal cancer patients. MATERIALS AND METHODS: In this clinical trial we...

Descripción completa

Detalles Bibliográficos
Autores principales: Aghili, Mahdi, Khalili, Nastaran, Khalili, Neda, Babaei, Mohammad, Farhan, Farshid, Haddad, Peiman, Salarvand, Samaneh, Keshvari, Amir, Fazeli, Mohammad Sadegh, Mohammadi, Negin, Ghalehtaki, Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society for Radiation Oncology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533412/
https://www.ncbi.nlm.nih.gov/pubmed/33012155
http://dx.doi.org/10.3857/roj.2020.00115
_version_ 1783590127817195520
author Aghili, Mahdi
Khalili, Nastaran
Khalili, Neda
Babaei, Mohammad
Farhan, Farshid
Haddad, Peiman
Salarvand, Samaneh
Keshvari, Amir
Fazeli, Mohammad Sadegh
Mohammadi, Negin
Ghalehtaki, Reza
author_facet Aghili, Mahdi
Khalili, Nastaran
Khalili, Neda
Babaei, Mohammad
Farhan, Farshid
Haddad, Peiman
Salarvand, Samaneh
Keshvari, Amir
Fazeli, Mohammad Sadegh
Mohammadi, Negin
Ghalehtaki, Reza
author_sort Aghili, Mahdi
collection PubMed
description PURPOSE: Colorectal cancer is becoming an increasing concern in the middle-aged population of Iran. This study aimed to compare the preliminary results of short-course and long-course neoadjuvant chemoradiotherapy treatment for rectal cancer patients. MATERIALS AND METHODS: In this clinical trial we recruited patients with rectal adenocarcinoma located from 5 cm to 15 cm above the anal verge. Patients in group I (short-course) received three-dimensional conformational radiotherapy with a dose of 25 Gy/5 fractions in 1 week plus concurrent XELOX regimen (capecitabine 625 mg/m(2) from day 1–5 twice daily and oxaliplatin 50 mg/m(2) on day 1 once daily). Patients in group II (long-course) received a total dose of 50–50.4 Gy/25–28 fractions for 5 to 5.5 weeks plus capecitabine 825 mg/m(2) twice daily. Both groups underwent consolidation chemotherapy followed by delayed surgery at least 8 weeks after radiotherapy completion. The pathological response was assessed with tumor regression grade. RESULTS: In this preliminary report on complications and pathological response, 66 patients were randomized into two study groups. Mean duration of radiotherapy in groups I and II was 5 ± 1 days (range, 5 to 8 days) and 38 ± 6 days (range, 30 to 58 days). The median follow-up was 18 months. Pathological complete response was achieved in 32.3% and 23.1% of patients in the short-course and long-course groups, respectively (p = 0.558). Overall, acute grade 3 or higher treatment-related toxicities occurred in 24.2% and 22.2% of patients in group I and II, respectively (p = 0.551). No acute grade 4 or 5 adverse events were observed in either group except one grade 4 hematologic toxicity that was seen in group II. Within one month of surgery, no significant difference was seen regarding grade ≥3 postoperative complications (p = 0.333). CONCLUSION: For patients with rectal cancer located at least 5 cm above the anal verge, short-course radiotherapy with concurrent and consolidation chemotherapy and delayed surgery is not different in terms of acute toxicity, postoperative morbidity, complete resection, and pathological response compared to long-course chemoradiotherapy.
format Online
Article
Text
id pubmed-7533412
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Korean Society for Radiation Oncology
record_format MEDLINE/PubMed
spelling pubmed-75334122020-10-14 Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial Aghili, Mahdi Khalili, Nastaran Khalili, Neda Babaei, Mohammad Farhan, Farshid Haddad, Peiman Salarvand, Samaneh Keshvari, Amir Fazeli, Mohammad Sadegh Mohammadi, Negin Ghalehtaki, Reza Radiat Oncol J Original Article PURPOSE: Colorectal cancer is becoming an increasing concern in the middle-aged population of Iran. This study aimed to compare the preliminary results of short-course and long-course neoadjuvant chemoradiotherapy treatment for rectal cancer patients. MATERIALS AND METHODS: In this clinical trial we recruited patients with rectal adenocarcinoma located from 5 cm to 15 cm above the anal verge. Patients in group I (short-course) received three-dimensional conformational radiotherapy with a dose of 25 Gy/5 fractions in 1 week plus concurrent XELOX regimen (capecitabine 625 mg/m(2) from day 1–5 twice daily and oxaliplatin 50 mg/m(2) on day 1 once daily). Patients in group II (long-course) received a total dose of 50–50.4 Gy/25–28 fractions for 5 to 5.5 weeks plus capecitabine 825 mg/m(2) twice daily. Both groups underwent consolidation chemotherapy followed by delayed surgery at least 8 weeks after radiotherapy completion. The pathological response was assessed with tumor regression grade. RESULTS: In this preliminary report on complications and pathological response, 66 patients were randomized into two study groups. Mean duration of radiotherapy in groups I and II was 5 ± 1 days (range, 5 to 8 days) and 38 ± 6 days (range, 30 to 58 days). The median follow-up was 18 months. Pathological complete response was achieved in 32.3% and 23.1% of patients in the short-course and long-course groups, respectively (p = 0.558). Overall, acute grade 3 or higher treatment-related toxicities occurred in 24.2% and 22.2% of patients in group I and II, respectively (p = 0.551). No acute grade 4 or 5 adverse events were observed in either group except one grade 4 hematologic toxicity that was seen in group II. Within one month of surgery, no significant difference was seen regarding grade ≥3 postoperative complications (p = 0.333). CONCLUSION: For patients with rectal cancer located at least 5 cm above the anal verge, short-course radiotherapy with concurrent and consolidation chemotherapy and delayed surgery is not different in terms of acute toxicity, postoperative morbidity, complete resection, and pathological response compared to long-course chemoradiotherapy. The Korean Society for Radiation Oncology 2020-06 2020-06-05 /pmc/articles/PMC7533412/ /pubmed/33012155 http://dx.doi.org/10.3857/roj.2020.00115 Text en Copyright © 2020 The Korean Society for Radiation Oncology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Aghili, Mahdi
Khalili, Nastaran
Khalili, Neda
Babaei, Mohammad
Farhan, Farshid
Haddad, Peiman
Salarvand, Samaneh
Keshvari, Amir
Fazeli, Mohammad Sadegh
Mohammadi, Negin
Ghalehtaki, Reza
Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial
title Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial
title_full Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial
title_fullStr Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial
title_full_unstemmed Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial
title_short Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial
title_sort short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533412/
https://www.ncbi.nlm.nih.gov/pubmed/33012155
http://dx.doi.org/10.3857/roj.2020.00115
work_keys_str_mv AT aghilimahdi shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial
AT khalilinastaran shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial
AT khalilineda shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial
AT babaeimohammad shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial
AT farhanfarshid shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial
AT haddadpeiman shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial
AT salarvandsamaneh shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial
AT keshvariamir shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial
AT fazelimohammadsadegh shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial
AT mohammadinegin shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial
AT ghalehtakireza shortcourseversuslongcourseneoadjuvantchemoradiotherapyinpatientswithrectalcancerpreliminaryresultsofarandomizedcontrolledtrial